NXGL Quote, Financials, Valuation and Earnings

OrthoPediatrics has a net margin of -27.95% compared to NexGel's net margin of -30.51%. NexGel's return on equity of -63.18% beat OrthoPediatrics's return on equity of -10.25%.

NexGel has a consensus price target of $6.00, signalling upside risk potential of 133.46%. On the other hand OrthoPediatrics has an analysts' consensus of $39.00 which suggests that it could grow by 71.81%. Given that NexGel has higher upside potential than OrthoPediatrics, analysts believe NexGel is more attractive than OrthoPediatrics.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison OrthoPediatrics has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.642%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OrthoPediatrics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. OrthoPediatrics pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $3M, which are smaller than OrthoPediatrics quarterly revenues of $52.7M. NexGel's net income of -$850K is higher than OrthoPediatrics's net income of -$16.1M. Notably, NexGel's price-to-earnings ratio is -- while OrthoPediatrics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 1.93x versus 2.56x for OrthoPediatrics. Usually stocks with elevated PS ratios are considered overvalued.

Innovative Eyewear has a net margin of -27.95% compared to NexGel's net margin of -307.83%. NexGel's return on equity of -63.18% beat Innovative Eyewear's return on equity of -105.44%.

NexGel has a consensus price target of $6.00, signalling upside risk potential of 133.46%. On the other hand Innovative Eyewear has an analysts' consensus of $9.00 which suggests that it could grow by 354.55%. Given that Innovative Eyewear has higher upside potential than NexGel, analysts believe Innovative Eyewear is more attractive than NexGel.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innovative Eyewear has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innovative Eyewear offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. Innovative Eyewear pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $3M, which are larger than Innovative Eyewear quarterly revenues of $690.7K. NexGel's net income of -$850K is higher than Innovative Eyewear's net income of -$2.1M. Notably, NexGel's price-to-earnings ratio is -- while Innovative Eyewear's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 1.93x versus 1.78x for Innovative Eyewear. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of -27.95% compared to NexGel's net margin of --. NexGel's return on equity of -63.18% beat Plus Therapeutics's return on equity of --.

NexGel has a consensus price target of $6.00, signalling upside risk potential of 133.46%. On the other hand Plus Therapeutics has an analysts' consensus of $9.38 which suggests that it could grow by 1088.06%. Given that Plus Therapeutics has higher upside potential than NexGel, analysts believe Plus Therapeutics is more attractive than NexGel.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.459%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $3M, which are larger than Plus Therapeutics quarterly revenues of --. NexGel's net income of -$850K is higher than Plus Therapeutics's net income of -$2.9M. Notably, NexGel's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 1.93x versus 0.97x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Staar Surgical has a net margin of -27.95% compared to NexGel's net margin of -69.92%. NexGel's return on equity of -63.18% beat Staar Surgical's return on equity of -5.02%.

NexGel has a consensus price target of $6.00, signalling upside risk potential of 133.46%. On the other hand Staar Surgical has an analysts' consensus of $18.67 which suggests that it could grow by 17.25%. Given that NexGel has higher upside potential than Staar Surgical, analysts believe NexGel is more attractive than Staar Surgical.

NexGel has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Staar Surgical has a beta of 0.747, suggesting its less volatile than the S&P 500 by 25.297%.

NexGel has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Staar Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NexGel pays -- of its earnings as a dividend. Staar Surgical pays out -- of its earnings as a dividend.

NexGel quarterly revenues are $3M, which are smaller than Staar Surgical quarterly revenues of $49M. NexGel's net income of -$850K is higher than Staar Surgical's net income of -$34.2M. Notably, NexGel's price-to-earnings ratio is -- while Staar Surgical's PE ratio is 49.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NexGel is 1.93x versus 2.51x for Staar Surgical. Usually stocks with elevated PS ratios are considered overvalued.